男科 妇科 骨科 耳鼻喉 肛肠 泌尿 不孕不育 皮肤病 口腔 肿瘤 糖尿病 眼病 性病 肝病 心血管 更多
中医网
您的位置:首页 > 疾病大全 > 癌症 > 肿瘤 > 膀胱癌 > 正文

膀胱癌患者血及肿瘤组织尿激酶含量的检测


注意阅读时间,健康用眼! 2013-08-28   中医诊疗网  www.zlnow.com

  abstract objective to study the upa level in the neoplastic tissue and peripheral blood of bladder cancer patients. methods 51 cases of transitional cell bladder cancer were studied by means of enzyme-linked immunosorbent assay (elisa). results upa content in neoplastic tissue of grade ⅲ tumors was obviously higher than that in grade ⅱ or grade ⅰ tumors

  department of urology,the affiliated hospital of binzhou medical college, shandong 256603

yang jinyi,li shao,zhou rongxiang,et al.

urokinase-type plasminogen activator (upa) in the neoplastic tissue and peripheral blood of bladder cancer patients

  摘要 目的 了解尿激酶型纤溶酶原激活剂(upa)与膀胱肿瘤恶性程度及浸润深度之间的关系。 方法 采用酶联免疫吸附实验(elisa)检测51例膀胱移行细胞癌病人术前、术后静脉血及肿瘤组织upa含量。 结果 g3肿瘤组织upa含量明显高于g1和g2(p均<0.01),g1与g2间upa差异无显著性;浸润癌肿瘤组织upa含量明显高于表浅肿瘤组织(p<0.05)。病人术前及术后静脉血upa含量与正常人静脉血upa含量差异无显著性。 结论 肿瘤组织upa含量可以反映膀胱肿瘤的恶性程度和肿瘤浸润深度。

微信搜索“zhongyikong”并关注,每天体验中医之道。
友情提示,一切诊断与治疗请遵从医生指导。京ICP备14033551号-10